Secretion" (Dr. Susumu Seino), "Neuromedin U is a Mammalian Decretin and Anti-Incretin" (Dr. Seung Kim), and "Physiological Function of GIP and Clinical Implications" (Dr. Yutaka Seino). The quality of all presentations was outstanding, generating many provocative questions and considerable discussion. It certainly is remarkable to see how far the field has come from Dr. Brown's discovery of the first incretin GIP, to the detailed knowledge of how incretin hormones work and the development of several effective incretin-based therapies for diabetes.
Aside from the science sessions, attendees were treated to a fireworks display, a dinner cruise around the inner harbor and Stanley Park, an outdoor salmon barbeque, and a night in the Museum of Anthropology. By all accounts the meeting was a success.
I wish to personally thank the numerous volunteers who spent many hours assisting me with various aspects of the conference planning and execution, particularly Dr. Maria Glavas and Sonia Serrambana. I would also like to extend my gratitude to our generous sponsors, including the Japan Association for Diabetes Education and Care (JADEC), AstraZeneca, Merck, Lilly, Boehringer Ingelheim, Canadian Diabetes Association, and the University of British Columbia, without which, this conference would not have been possible.
I sincerely hope you enjoy the contents of this supplemental issue and please consider joining us the next time an INCRE-TIN conference is organized.
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